The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.
Inclusion Criteria: 1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage, 2. Man or woman ≥ 18 years, 3. Obtaining of the informed consent signed before any procedure of specific preselection on approval. Exclusion Criteria: 1. Private persons of freedom or under guardianship, 2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons, 3. Pregnant woman and/or breast-feeding, 4. Unaffiliated patient to Social Protection System,